Compare GIS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | GMAB |
|---|---|---|
| Founded | 1866 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | 3088 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 16.5B |
| IPO Year | 2004 | N/A |
| Metric | GIS | GMAB |
|---|---|---|
| Price | $36.03 | $28.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $42.07 | $39.56 |
| AVG Volume (30 Days) | ★ 10.8M | 2.0M |
| Earning Date | 03-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,037,800,000.00 | N/A |
| Revenue This Year | N/A | $17.85 |
| Revenue Next Year | N/A | $16.04 |
| P/E Ratio | ★ N/A | $1.90 |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $31.75 | $21.00 |
| 52 Week High | $51.33 | $35.43 |
| Indicator | GIS | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 60.32 |
| Support Level | $35.45 | $28.07 |
| Resistance Level | $38.09 | $29.70 |
| Average True Range (ATR) | 1.10 | 0.71 |
| MACD | -0.19 | -0.06 |
| Stochastic Oscillator | 19.65 | 58.91 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.